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Objective: To examine the influence of pre-experimental stress on the anxiogenic-like action of caerulein,
an agonist of cholecystokinin (CCK) receptors. Differences in the anxiety levels of rats in summer and win-
ter, and the role of CCK in these behavioural alterations, were also examined. Design: Prospective ani-
mal study. Interventions: Male Wistar rats were injected with the CCK agonist caerulein, or the CCK
antagonists L-365,260 or devazepide, after being exposed to pre-experimental stress (handling and isola-
tion).Outcome measures: Performance in the plus-maze model of anxiety; serum levels of prolactin, thy-
rotropin and growth hormone; brain density and affinity of dopamine D2, serotonin 5-HT2 and CCK recep-
tors. Results: Caerulein (5 pg/kg, subcutaneous injection) caused the strongest action in animals brought
to the experimental room immediately before the experiment and kept in isolation after the administra-
tion of caerulein. Caerulein did not cause any reduction of exploratory activity in rats made familiar with
the experimental room and kept in the home-cage after the injection of the CCK agonist. The anti-
exploratory action of caerulein in stressed rats was reversed by the CCK antagonist L-365,260 (I100 pg/kg,
intraperitoneal injection), demonstrating the involvement of the CCKB receptor subtype. In addition, sea-
sonal fluctuations occur in the exploratory activity of rats; such activity was much lower in July than in
November. The rats displaying the reduced exploratory activity had an increased number of CCK recep-
tors in the frontal cortex and hippocampus. Simultaneously, the density of serotonin 5-HT2 receptors in
the frontal cortex, but not that of dopamine D2 receptors in the striatum, was elevated. The blood level
of growth hormone was also higher in July. Conclusions: The anti-exploratory action of caerulein appears
to be dependent on the pre-experimental stress of rats. Moreover, the seasonal variations of exploratory
behaviour of rats are evident in the plus-maze model of anxiety. The reduced exploratory activity in sum-
mer appears to be related to the elevated density of CCK and 5-HT2 receptors in the brain.
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Objectif: Etudier l'influence du stress pre-experimental sur 1'effet quasi anxiogene de la ceruleine, agoniste des
recepteurs de la cholecystokinine (CCK). On a aussi etudie les differences entre les niveaux d'anxiete chez les
rats l'6te et l'hiver et le r6le de la CCK dans ces modifications du comportement. Conception: etude prospec-
tive sur animaux. Interventions: On a injecte a des rats Wistar males de la ceruleine, agoniste de la CCK, les
antagonistes L-365,260 de la CCK ou du devazepide, apres les avoir expose a un stress pre-experimental (manipu-
lation et isolement). Mesures de resultats: Performance dans le labyrinthe (un modele d'anxiete); taux seriques
de prolactine, de thyrotropine et d'hormone de croissance; densite cerebrale et affinite des recepteurs de la
dopamine D2, de la serotonine 5-HT2 et de la CCK. Resultats: La ceruleine (injection sous-cutanee de 5 pg/kg)
a eu 1'effet le plus marque chez les animaux transportes a la salle experimentale immediatement avant l'experience
et gardes en isolement apres I'administration de la ceruleine. La ceruleine n'a pas provoque de reduction de
l'activite exploratoire chez les rats qui ont appris a connaitre la salle experimentale et ont ete gardes dans leur
cage habituelle apres l'injection de l'agoniste de la CCK. L'action anti-exploratoire de la ceruleine chez les rats
stresses a ete contree par I'antagoniste L-365,260 de la CCK (injection intraperitoneale de 100 pg/kg), ce qui
demontre le role du sous-type recepteur de la CCKB. On enregistre en outre des fluctuations saisonnieres de
l'activit6 exploratoire des rats, qui est beaucoup plus basse en juillet qu'en novembre. Les rats qui ont montre
une baisse de l'activite exploratoire avaient davantage de recepteurs de la CCK dans le cortex frontal et l'hippo-
campe. En meme temps, la densite des recepteurs de la serotonine 5-HT2 dans le cortex frontal etait elevee, mais
celle des recepteurs de la dopamine D2 dans le striatum ne l'etait pas. Le taux sanguin d'hormone de croissance
etait aussi plus eleve en juillet. Conclusions: L'action anti-exploratoire de la ceruleine semble liMe au stress pre-
exp6rimental chez les rats. De plus, le labyrinthe montre les variations saisonnieres du comportement explora-
toire des rats. La baisse de l'activite exploratoire au cours de l'ete semble liee a l'elevation de la densite des recep-
teurs de la CCK et 5-HT2 dans le cerveau.
Introduction
Cholecystokinin octapeptide (CCK-8) is a widely dis-
tributed neuropeptide in the mammalian brain.' Recent
evidence suggests that CCK-8 is involved in the neuro-
biology of anxiety.2 The anxiogenic-like action of CCK
agonists is established in various animal species,
including the monkey, guinea-pig, rat, mouse and cat.3
CCKB-receptor (brain subtype) antagonists are effective
in antagonizing the anxiogenic-like action of CCK ago-
nists, but they also cause an anxiolytic-like effect in var-
ious animal models of anxiety.2'" There is a growing
body of evidence that the administration of the CCK8-
receptor agonists CCK-4 and pentagastrin induces
panic-like attacks in healthy volunteers and patients
suffering from panic disorder.4'79 The sensitivity of
patients with panic disorder to the panicogenic action
of CCKB agonists is significantly higher than that of
healthy subjects.8 The striking similarity between CCK-
induced panic-like attacks and natural attacks has been
established in patients with panic disorder. The aug-
mented response to CCK agonists is also described in
patients suffering from other anxiety disorders.3
Accordingly, increased sensitivity to CCKB-receptor
agonist-induced panic-like attacks seems to be a com-
mon feature of anxiety disorders. The pretreatment of
healthy subjects with CCK8-receptor antagonists blocks
the panicogenic action of CCKB agonists, demonstrating
a role for CCK, receptors.6
There is some evidence that the response of rats to the
anxiogenic-like action of CCK may be dependent on the
level of pre-experimental stress.2 Biro et all' have
demonstrated that the anxiogenic-like action of CCK is
related to the release of corticotropin-releasing hor-
mone (CRH). CRH obviously plays a key role in the
behavioural and hormonal mechanisms of stress."
Recent studies have shown that mice lacking the CRH1
receptor display impaired stress response and reduced
anxiety in the light/dark compartment test.'2"13 The
results obtained from the clinical studies provide some
evidence for an altered activity of CRH in anxiety dis-
orders, but apparently less than that seen in depres-
sion.""l' Patients suffering from panic disorder display
increased sensitivity to CRH-induced corticotropin and
cortisol release.18 The administration of the CCK8-recep-
tor agonists CCK-4 and pentagastrin has been shown to
activate the hypothalamic-pituitary-adrenal axis.7'19'20 In
their recent study, Koszycki et a121 found that the
administration of CCK-4 significantly enhanced corti-
cotropin secretion in healthy volunteers responding
with panic-like attacks compared with nonresponders.
In the present study, an attempt was made to clarify the
significance of pre-experimental stress on the anxio-
genic-like action of CCK.
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Several investigators have described the seasonal
fluctuations in anxiety. Recent reports have described a
higher incidence in the occurrence of first panic attacks
in the summer, irrespective of the hemisphere in which
the study was carried out.22-24 Lelliott et aP have found
that, of 57 patients with panic disorder with agorapho-
bia, more had their first panic attack in late spring and
summer than in fall and winter, and in warm weather
than in cold weather. Therefore, the second major goal
of the present study was to investigate the differences in
the anxiety levels of rats in summer and winter, and the
role of CCK in these behavioural alterations. Simul-
taneously, changes in the density of serotonin 5-HT2
and dopamine D2 receptors, and in the blood levels of
anterior pituitary hormones (prolactin, growth hor-
mone and thyrotropin), were studied.
Methods
Animals
Male Wistar (Han/Kuo: WIST) rats (National Animal
Center, Kuopio, Finland) weighing 250 to 300 g were
kept 4 per cage in the animal house at 20 ± 2°C in a 12-
hour light/dark cycle (light on at 7:00 am). Tap water
and food pellets were available ad libitum.
Behavioural studies
Two different studies were performed. In the first part
(study performed in November and December), an
attempt was made to assess the significance of pre-
experimental stress on CCK-induced anxiety in the ele-
vated plus-maze. For that purpose, one half of the rats
were habituated to the experimental situation ("han-
dling"), but the others were not ("non-handling").
Stressful influences were the lack of handling and brief
isolation just before the exposure to the elevated plus-
maze. Stress-reducing influences were handling (as
habituation to the experimenter and experimental situ-
ation) and nonisolation before behavioral test (animals
were placed back to the home cage after the injection).
The male Wistar rats were divided into 4 different
groups. Two groups of rats were handled in the exper-
imental room on 3 consecutive days (twice daily) before
the experiment. The other 2 groups of animals were
brought to the experimental room immediately before
the beginning of experiment. The handled and non-
handled rats were divided into 2 groups after the injec-
tion of caerulein (5 pg/kg, subcutaneous injection;
Sigma, US), an agonist of CCK receptors. Caerulein or
saline solution was injected 15 minutes before the
beginning of the plus-maze study. One half of the ani-
mals were isolated after the injection, whereas the other
half were placed back into the home-cage. The action of
the CCKB antagonist L-365,260 (1 to 100 pg/kg,
intraperitoneal injection; Merck Sharp & Dohme, UK)
and the CCKA antagonist devazepide (1 to 100 pg/kg,
intraperitoneal injection; Merck Sharp & Dohme) on the
anxiogenic-like action of caerulein was studied in the
animals not exposed to handling and kept in isolation
after treatment with the CCK agonist. CCK antagonists
or vehicle (2% Tween-85, Sigma, US) in physiological
saline solution) were injected 30 minutes before the
plus-maze study.
In the second half of the study, possible seasonal dif-
ferences in the exploratory activity of rats were investi-
gated. Two experiments were performed one was
conducted at the beginning of July 1993 (summer) and
the other in late November of 1994 (winter). This study
was performed in 40 handling-naive rats (in both exper-
iments). The animals were decapitated immediately
after the plus-maze exposure, and blood and brain sam-
ples were taken for neurohormonal studies.
The elevated plus-maze
The method initially suggested by Handley et al2V for
the measurement of exploratory activity was employed
with some modifications.26 The apparatus consisted of 2
opposite open arms (50 x 10 cm) without side walls and
2 enclosed arms (50 x 10 x 40 cm) with side walls and an
end wall, extending from a central square (10 x 10 cm).
The maze was elevated to the height of 50 cm, and
placed in a lit room. During a 5-minute observation ses-
sion the following measures were taken by an observer:
1) latency of first open part entry; 2) time spent in
exploring of open part and open arms of plus-maze; 3)
number of closed and open arm entries; 4) number of
lines crossed; and 5) ratio between open and total arm
entries. At the beginning of the experiment, an animal
was placed into the centre of the plus-maze, facing
toward a closed arm. An arm entry was counted only
when all 4 limbs of the rat were within a given arm.
Time spent in open arms, number of open arm entries
and ratio between open and total arm entries are the
"classic" measures of anxiety in the elevated plus-
maze. By contrast, the number of closed arm entries
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and number of line crossings are the measures reflect-
ing the locomotor activity of rats.27
Hormonal studies
The animals were killed by decapitation immediately
after the plus-maze exposure. In all cases, the truncal
blood was collected, serum was separated by centrifu-
gation and samples were stored at -200C until prolactin,
thyrotropin and growth hormone concentrations were
determined from duplicate samples (0.1 mL) by specif-
ic radioimmunoassays. The rat prolactin, thyrotropin
and growth hormone kits were gifts from the US
National Institutes of Health. Prolactin results are
expressed in ng/mL of NIDDK-rPRL-RP-2 standard.
T'hyrotropin data are expressed in ng/mL of NIDDK-
TSH-RP-2 standard. Growth hormone results are
expressed in ng/mL of NIDDK-GH-RP-2 standard.
Each hormone was assayed in a single session. The
intra-assay coefficient of variation was less than 15%.
Radioligand binding studies
For the radioligand binding studies, 28 rats from the
study performed in the summer and 28 rats from the
study performed in the winter were used. After decap-
itation, the brains were quickly dissected on ice. The
binding studies were performed on various brain struc-
tures. The striatum was used to determine the density
and affinity of dopamine D1½ receptors, the frontal cortex
for serotonin 5-HT2 receptors and CCK receptors, and
the hippocampus for CCK receptors (Table 1). These
brain structures were selected according to previous
studies, since it is in these brain regions that the most
significant neurochemical changes due to elevated plus-
maze exposure were observedtM-3The brain tissue was
homogenized in ice-cold 50 mmol/L Iris-hydrochloric
acid (pH 7.4 at 40C; 20 x volume) using a Potter-S glass-
teflon homogenizer (1000 rpm, 12 passes). The mem-
branes were washed twice in the same buffer by cen-
trifugation (48000 x g for 20 minutes) and resuspended-.
After the last centrifugation, the crude brain mem-
branes were suspended in the incubation buffer for the
appropriate binding assay.
The protein content was measured according to a
dye-binding assay.3 Saturation curves were analyzed
using non-linear regression analysis.'
Statistics
The behavioural studies with caerulein and CCK antag-
onists were analyzed using one-way analysis of vari-
ance (ANOVA). Post hoc comparisons between individ-
ual groups were performed using the Newman-Keuls
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test with the Statistica for Windows software (Statsoft,
the Netherlands). Comparison between experiments
performed in July and November were assessed using
the Student's t-test.
Results
The anti-exploratory action of caerulein (5 pg/kg) was
dependent on the pre-experimental handling and isola-
tion of the rats. Caerulein did not cause any reduction
in the exploratory activity of rats who were subjected to
the handling and kept in the home-cage after the injec-
tion of the CCK agonist (Table 2). Caerulein tended to
reduce the activity of rats who were not handled but
kept in the home-cage; however, this change was not
statistically significant. In the third group, in which the
rats were handled but kept separated after the treat-
ment, caerulein apparently reduced the exploratory
activity of rats in the elevated plus-maze. Caerulein had
the strongest effect in rats not subjected to the handling
and kept in isolation after treatment with the CCK ago-
nist (Table 2; number of line crossings F7,92 = 4.58, p <
0.01; number of open arm entries F792 = 3.36, p < 0.01;
time spent in open arm F7,9 = 2.31, p < 0.05; number of
total arm entries F7,92 = 4.51, p < 0.01; ratio between open
and total arm entries F7,92 = 2.79, p < 0.05).
The anti-exploratory effect of caerulein in the stressed
rats (i.e., no handling plus isolation) was antagonized by
L-365,260 (1 to 100 jig/kg), an antagonist of CCKB recep-
tors, in a dose-dependent manner (Table 3; time spent in
open part F4,6 = 2.90, p < 0.05; number of line crossings
F40= 3.18, p < 0.05; number of open arm entries F4,66 =
2.53, p < 0.05; time spent in open part F4,6 = 2.57, p < 0.05;
number of total arm entries F4,6 = 2.94, p < 0.05; ratio
between open and total arm entries F46 = 2.63, p < 0.05).
L-365,260 at 1 jig/kg, administered together with
caerulein, tended to reduce locomotor activity; this com-
bination decreased the number of line crossings and total
arm entries. However, 10 jig/kg of L-365,260 tended to
antagonize the anti-exploratory action of caerulein,
whereas 100 pg/kg of the CCK antagonist completely
reversed the effect of the CCK agonist. L-365,260 at 10
pg/kg increased the exploratory activity of stressed rats
(i.e., no handling plus isolation) in the elevated plus-
maze (time spent in exploring of open arms, F361 = 2.62, p
< 0.05; ratio between open and total arm entries F3,61 =
3.05, p < 0.05), whereas the lower (1 pg/kg) and higher
doses (100 pg/kg) of CCKB antagonist were ineffective in
this respect (Table 4). Devazepide, an antagonist of CCKA
receptors, also antagonized the action of caerulein in the
plus-maze (Table 5; time spent in open part F4,35 = 4.79, p
< 0.01; number of line crossings F435 = 4.88, p < 0.01; num-
ber of total arm entries F43 = 3.02, p < 0.05). The highest
dose of devazepide (100 pg/kg) counteracted the anti-
exploratory effect of the CCK agonist. The administra-
tion of devazepide as a single treatment did not affect the
exploratory activity of rats in the plus-maze (Table 6).
The exploratory activity of rats in November was sig-
nificantly higher than in the similar study conducted in
July (Table 7). All the studied plus-maze parameters
were significantly different if the data from these 2 stud-
ies were subjected to statistical analysis. The rats from the
summer study had higher densities of CCK receptors in
the frontal cortex and hippocampus, compared with rats
from the winter study (Table 8). The number of serotonin
5-HT2 receptors in the frontal cortex, but not dopamine
D2 receptors in the striatum, was also increased in rats
from the summer study. The rats from the studies per-
Mean (and stndard error oF the mean)
Vehide + L365,260, i/kg +
Vehicle + saline caerulein, 5 W/kg caerulein, 5 ig/kg
L365,260, 10 Pigkg +
caerulein, 5 pglkg
Parameter n= 14 n1=A4 n= 14 n= 14 n= 14
Number ofline crssings 22 (1.9) 17 (1.5) 14* (2.3) 18t (1.8) 22 (2)
rimespentinopenpart,s 135 (13) 96 (8) 100 (16) 132t (14) 143t (I1)
Number of open arm enties 1.3 (0-4) 0.4* (0.2) 0.4* (0.2) 1.0 (O). 1.3 (0.4)
Timespentin'penarm,s .30 (10) 5* (3) 8 (4) 7.7t (0.9) 3It (I1)
Number of total arm entries 6.3 (0.7) 5.5 (0.6) 4* (0.7) 5A (0.6) 6.9t (0-6)
Ratio between open/wol
armentriesx 100 19 (5) 6* (2) 8 (4) 22 (6) 15 (5)
*p 0.05 (cpard wkh vehkie plus saline treated rats; Newman-Keuk tae after signAicant one-way ANOVA)






formed in the different seasons also differed in blood lev-
els of growth hormone, but not in levels of thyrotropin
and prolactin (Table 9). The rats from the summer study
had increased levels of growth hormone.
Discussion
The present study revealed a clear dependence of the
anti-exploratory effect of caerulein on pre-experimental
stress. In animals made familiar with the experimiental
situation and kept in the home-cage after the injection of
caerulein, the CCK agonist did not increase anxiety in
the elevated plus-maze. On the other hand, in rats
brought into the experimental room immediately before
the study and kept in isolation after the treatment with
caerulein, the CCK agonist caused a significant anxio-
Mean (and'stt'dm% error of-dte mean)'
L365,.260, U65M3
Vehicle L-365,260, I pg/kg 10 pgkg 100 p/k
Parameters ~~~~~~n16 n16. n 16 n 14
on,be on.csings 20 (.) 20 (3) 22 (3.2) 1 12
Timespetifno0Pampa,.$ lOt (.10) 116 (1.1) 125 (1-2) 97 (;I%
Nwnbrfw ar enis 039 (2.7) 1.1 '(0.33) 1.6 (04) 0.7 (0.24)
Th"Veyethpear,s 12 (4) 26 (7) 30r (II1) 8 (3
Numberi- -dtw-*ihrmnntries 6. (0.8), 612 (1.0) 6.5 (0.8) 5.8 9
Ratio b~"etwe oMstoarm
entIe 10010 () 16 .(4) 25* (7) .8 (3







Timiesp eParts 175 (II1) 1.02*- (17) 126 (19)
1.0 ( 0.3 (0 12) 0.4 (0.4)
T1oweqVenthtopena rm,s 21 (1-2) 8, (6) 10 ..(7)
t*n oltotal' arm 5.4 (0.7) 2.5 (0.5) 3 (0.7)
RMIo'btwe open/total arm
entries xlI00 16 (6.) 7 (5) 5 (5S)
*p a (vowlilwe4w Adp hes dim erwSr w ." OAakne Wfte citiu one.w ayANOVA)
'0.05 (com wih o b .ptw nwes
arderror odfite'mean).




82*' (23) 11 (1.3)
0.5 (0.3) 0.8 (0.4)
9 (5 21 (2
3.4 (09) 5.5 (0,5)
II1 (6). I (4
Mean0(MM staard ,error of tue.mean)
Deapde, Dewimepide,- DevaepIde
Vehicle I ±g/Jc IOg/c IOOpg/kg
Parameters n 10 n=10' n10o n1=I
of.berolkncr6sskWg 14 (3.6) 8 (2.1) 13 (.) I (2.2).
Tkne spentliWuspena..t.'s 126 (25S) 117 (19) I0U (1*) I15 (15-).
Number ol optun-arm'entries 0.8 (0.31) 0.6 (0.32) 0.3 (0.16) 03. (0.-1*)
Irtie spentlf.qpeanarm,s 12 (7) 7 (4). 5 (3) .9 -(7)-
.NmberoftoWmamni4.6 (1.1) 2.9 .(0.7) 3.8S (.8) 4.0 (0D.9)
Raiob be6twen oe/ta' arm
entriesx 100 10 (4) 1 3 (7) 6 (4)4 (3
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genic-like action. This finding is in accordance with pre-
vious studies showing the presence of an anxiogenic-
like action of CCK alone in a novel environment.37
Moreover, CCK antagonizes morphine-induced analge-
sia in rats in novel, but not in familiar, experimental con-
ditions.?8 Accordingly, caerulein seems to potentiate
neophobia in rats. However, novelty is not the only fac-
tor determining the action of caerulein in the plus-maze.
Keeping of rats in social isolation after the injection of
CCK also contributes to the action of caerulein.
In our previous studies, we have found that the social
isolation of rats for 7 days induced anxiety and
increased the density of CCK, but not benzodiazepine,
receptors in the frontal cortex.39 Therefore, it is likely
that the social isolation of rats sensitizes them to the
anxiogenic-like effect of caerulein. It has also been
shown that pre-experimental stress increases the effec-
tiveness of anxiolytic drugs in the plus-maze, demon-
strating that endogenous tone is an important factor to
consider when studying anxiety in rodents.' It is
important to point out that patients suffering from anx-
iety disorders are also more sensitive to CCK-4- and
pentagastrin-induced panic attacks than healthy volun-
teers.54' A characteristic feature of anxiety disorders is
an increased serum level of stress hormones (cortico-
tropin, cortisol).'7"9 Collectively, the level of pre-experi-
mental stress is a factor determining a potential
response to the anxiogenic-like action of CCK agonists,
both in animals and humans.
The potentiation of neophobia induced by caerulein
was antagonized by the CCK antagonists L-365,260 and
devazepide, in a dose-dependent manner. The highest
dose (100 pg/kg) of L-365,260 and devazepide com-
pletely reversed the action of caerulein. The nearly
equal potency of L-365,260 and devazepide against
caerulein makes it unlikely that this effect of CCK
antagonists is mediated primarily via CCKA receptors.
Devazepide has a very high affinity for CCKA receptors,
but it is relatively nonselective at higher doses (above 10
pg/kg) and has much better penetration into the brain
than L-365,260.42 Therefore, the CCK8-receptor subtype
is a likely target for the anxiogenic-like action of
caerulein. This is in agreement with previous studies
showing a key role of CCKR receptors in CCK-induced
anxiety, both in human and animal studies."643 The sin-
gle treatment with L-365,260-, but not with devazepide-
induced anxiolytic-like action in rats. However, the
action of L-365,260 was not dose-dependent, since only
1 dose of the CCKB receptor antagonist (10 pg/kg) was
effective, whereas the lower and higher doses did not
change the exploratory behaviour of the rats. The U-
shaped action of L-365,260 has been also established in
Mean (standard error of the mean)
Plus-maze parameters July November
Number of line crossings 10 (I) 28* (2)
Time spent in open part, s 46 (6) 91* (6)
Number of open arm entries 0.2 (0.1) 1.3* (0.3)
Time spent in open arm, s 4 (2) 14* (3)
Number of totl arm entries 3.1 (0.3) 7.8* (0.6)
Ratio between open/total
arm entries x 100 4 (2) 19* (4)





*p < 0.05, Student's t-test
Mean (standard error of the
mean)
July November
1.6 (0.2) . 1.2 (0.2)
35 (4) 13* (2)
15 (2) II (I)
Radioligand binding
in the brain structures Kd, nmol/L protein Kd, nmol/L protein
[3H]pCCK-8 in the frontal cortex 0.87 (0.08) 8.7 (0.4) 0.79 (0.05) 6.1* (0.3)
[3H]pCCK-8 in the hippocampus 0.77 (0.07) 5.3 (0.3) 0.58* (0.06) 3.7* (0.3)
r[H]spiperone in the striatum 0.59 (0.06) 214 (8) 0.75 (0.10) 198 (8)
[3H]spiperone in the frontal cortex 1.52 (0.25) 140 (18) 1.11 (0.11) 106* (5)
'p < 0.05, Stuen's t-test
no 1,2000 Joursu.I of A. .I.woeeie.ce
Mean (and standard error of the mean)
July November
B., fmol/mg B,, fmnol/mg
.7 E.
i'4so *'.'^'.tiE:0:i'.9:i)E't'l ^j St[ga I Q . ,i: ........... ^E.&.j:Ew .......... '.:
'4: m '!'wo, 4'-> n
our previous studies,4' but the mechanism underlying
this peculiar action remains to be established.
The present study also provides strong evidence for
the seasonal variations in the exploratory activity of
rats. The comparison of the exploratory activities of rats
in experiments conducted in July (summer) and in
November (winter) revealed a clear difference, namely,
that the exploratory activity was much lower in sum-
mer compared with winter. Similar results showing a
significant variation in the exploratory activity of rats in
studies performed in November and in June were
obtained by Harro et al.45 Moreover, it is important to
stress that the anxiogenic-like action of caerulein is
much weaker in summer than in winter (unpublished
data). This was why the influence of pre-experimental
stress on the anxiogenic-like action of CCK agonist was
studied in winter but not in summer.
These data are also interesting in light of recent
reports describing a significantly higher incidence of
first panic attack in summer than in winter.',24' The
hypothetical reason for such seasonality is the increased
activity of people in summer, which leads to over-
crowding of public places." In rats, the increased level
of anxiety in summer could be explained by the higher
pressure from the surrounding nature; in summer the
number of potential predators is much higher than in
winter, when life in nature is apparently slowing down.
This statement is supported by recent findings showing
seasonal fluctuations in the serum levels of corti-
cotropin in the sand rat, with the maximum concentra-
tion occurring during the late spring and summer.47
The reduced exploratory activity of rats in summer
appears to be related to the increased number of CCK
receptors in the frontal cortex and hippocampus. Harro
et al45 have reached the same conclusions, i.e., that in
June, when exploratory activity is lower, the density of
CCK receptors is higher in the frontal cortex, hippo-
campus and striatum, but not in the hypothalamus. In
light of these data, it is likely that the tone of CCKergic
transmission is higher in summer than in winter. This
could be a possible explanation why the anxiogenic-like
action of caerulein is much weaker in summer; that is,
CCK receptors seem to be occupied by the endogenous
ligand. In addition, we have noted an increased density
of serotonin 5-HT2 receptors in the frontal cortex of rats
with decreased exploratory activity. By contrast, the
number of dopamine D2 receptors in the striatum
remained unchanged. Accordingly, increased anxiety
in rats seems to be related to the increased density of
CCK and serotonin 5-HT2 receptors in the forebrain.
In summer, rats had significantly increased levels of
growth hormone, whereas the levels of prolactin and
thyrotropin remained unchanged. A recent study has
shown that healthy subjects respond to CCK-4 challenge
with an increased level of growth hormone, which was
higher in those who panicked after CCK-4 than in non-
panickers.21 In a previous study, we investigated the
release of anterior pituitary hormones in relation to the
exploratory behaviour of rats.u In that study, neither the
exposure of rats to the plus-maze nor distinctive
exploratory activity correlated with the serum levels of
the anterior pituitary hormones, prolactin or thyrotropin.
Only the concentrations of growth hormone were signif-
icantly different in the rats selected according to their
exploratory behaviour; that is, the "non-anxious" rats
had markedly lower levels of growth hormone than the
"anxious" and intermediate groups. Anterior pituitary
hormones are regulated by a multitude of classic neuro-
transmitters such as serotonin and dopamine, but also by
neuropeptides.49 It has been shown that serotonin stimu-
lates the baseline release of growth hormone and may be
involved in the stress-induced growth hormone eleva-
tion in humans.`0 CCK also participates in the regulation
of growth hormone. The activation of CCKA receptors
inhibits growth hormone secretion, whereas the activa-
tion of CCKB receptors increases it.5"'52 Therefore, the aug-
mented levels of growth hormone in the "anxious" ani-
mals might be caused by the increased activity of sero-
tonin and CCK in the brain.
Conclusion
We found that the anxiogenic-like action of caerulein
was dependent on pre-experimental stress in animals.
The CCK agonist had the strongest effect in rats not
adapted to the experimental conditions. In addition,
seasonal variations of exploratory activity were
revealed in the present study; the rats were more active
in winter than in summer. The reduced exploratory
activity of rats was apparently related to the increased
density of CCK and serotonin 5-HT2 receptors in the
brain. Also, the levels of growth hormone were
markedly higher in animals displaying reduced
exploratory activity. There is a striking similarity
between these animal studies and previous human
studies. The obvious relation to stress, increased sensi-
tivity to CCK and seasonal variations are also apparent
in human anxiety.
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